Geneoscopy

Saint Louis, MO · Founded 2015 · Privately Held (backing)

Developer of a molecular diagnostic platform designed to prevent, detect, and monitor gastrointestinal diseases through noninvasive testing. Geneoscopy is based in Saint Louis, MO and was founded in 2015. It was valued at $440 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $218 million across 2 recorded rounds; the latest was a $50.5 million later-stage round in May 2021.

PMV mark · valuation
$440.0M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$218.4M
Last round
Later Stage VC
May 2021
What is Geneoscopy worth?
$440.0MPrivateMarketView mark · Oct 2026

Valued at $440.0M at its later-stage round, Jan 2025. Nothing has traded since.

Free account
More of Geneoscopy with a free account
  • ·The complete investor list: 24 names
  • ·Watch Geneoscopy: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Geneoscopy funding history

2 rounds
DateRoundRaisedPost-money
May 2021Later Stage VC$50.5M▮
Sep 2019Early Stage VC$7.9M▮
Unlock post-money valuations

Membership and data by Private Market View

Geneoscopy valuation

Geneoscopy was valued at $440 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Geneoscopy raised?

Geneoscopy has raised $218 million in total; 2 of its rounds are on record. The largest on record was a $7.9 million early-stage round in Sep 2019; the most recent was a $50.5 million later-stage round in May 2021.

Geneoscopy has filed 2 Form Ds with the SEC since 2019, most recently in Nov 2021 ($50.5 million sold to 85 investors).

Institutional holders and vehicles

In the last 12 months, 1 investment vehicle was formed to buy Geneoscopy shares, reporting $801,750 sold to 22 investors, per SEC Form D filings (most recent Jan 2026).

How Geneoscopy's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Geneoscopy, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Geneoscopy

What is Geneoscopy worth?
Geneoscopy is valued at $440.0M as of Oct 2026. Valued at $440.0M at its later-stage round, Jan 2025. Nothing has traded since.
How much has Geneoscopy raised?
Geneoscopy has raised $218.4M in total funding across 2 recorded rounds.
When did Geneoscopy last raise?
Geneoscopy last raised in May 2021 (Later Stage VC), raising $50.5M.